Xue 1995.

Methods	Randomised clinical trial including 4 arms: transarterial chemoembolisation (TACE) with immediate administration of doxorubicin versus TACE with delayed administration of doxorubicin versus TACE plus external beam radiotherapy (EBRT) versus EBRT alone. Parallel‐group design
Participants	82 people with hepatocellular carcinoma Average age: 48.3 years Male/female: 69/13 Recruitment: March 1991 to April 1993
Interventions	TACE with immediate administration of doxorubicin (20 participants) versus TACE with delayed administration of doxorubicin (20 participants) versus EBRT + TACE (21 participants) versus EBRT alone (21 participants)
Outcomes	Tumour regression Survival Change of alpha‐fetoprotein
Notes	Child‐Pugh A: 36 Child‐Pugh B: 46 Country of the study: China We were unable to locate a contact email for the corresponding author to request missing data. Funding: unclear
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	The study was described as a randomised clinical trial, but the method of randomisation was not mentioned.
Allocation concealment (selection bias)	Unclear risk	The method used to conceal the allocation was not described.
Blinding of participants and personnel (performance bias) All outcomes	High risk	The trial was not blinded, so that the allocation was known during the trial.
Blinding of outcome assessment (detection bias) All outcomes	High risk	Outcome assessment was not blinded.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	There were insufficient data to assess attrition bias.
Selective reporting (reporting bias)	High risk	The trial did not report cancer‐related mortality, quality of life, or serious adverse events.
For profit bias	Unclear risk	Unclear funding source
Other bias	Unclear risk	Unclear risk of other bias